The safety and efficacy of gemcitabine for the treatment of bladder cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The safety and efficacy of gemcitabine for the treatment of bladder cancer
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume 16, Issue 3, Pages 255-271
Publisher
Informa UK Limited
Online
2016-01-19
DOI
10.1586/14737140.2016.1143777
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bladder Cancer
- (2017) Peter E. Clark et al. Journal of the National Comprehensive Cancer Network
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Diagnosis and Staging of Bladder Cancer
- (2015) Maxine Sun et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Epidemiology of Bladder Cancer
- (2015) Núria Malats et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
- (2015) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial
- (2015) Cora N Sternberg et al. LANCET ONCOLOGY
- A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma
- (2014) Maha Hussain et al. CANCER
- Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Invasive Transitional and Squamous Cell Carcinoma of the Bladder: Effect on Survival and Bladder Preservation
- (2014) Hussein M. Khaled et al. Clinical Genitourinary Cancer
- Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer
- (2014) Lucas de Sousa Cavalcante et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer
- (2014) Takuya Koie et al. MEDICAL ONCOLOGY
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)
- (2013) Susanne Krege et al. BJU INTERNATIONAL
- A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder
- (2013) Zeynep Eroglu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysis
- (2013) Firas Abdollah et al. Cancer Epidemiology
- EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
- (2013) Marko Babjuk et al. EUROPEAN UROLOGY
- Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials
- (2013) Jeffrey J. Leow et al. EUROPEAN UROLOGY
- Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer
- (2013) Arjun V. Balar et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase II Study of Gemcitabine and Irinotecan in Patients With Locally Advanced or Metastatic Bladder Cancer
- (2012) Uzair B. Chaudhary et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)
- (2012) A. Bamias et al. ANNALS OF ONCOLOGY
- A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer
- (2012) Arlene O. Siefker-Radtke et al. CANCER
- Use of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Is Low Among Major European Centres: Results of a Feasibility Questionnaire
- (2012) Maximilian Burger et al. EUROPEAN UROLOGY
- A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer
- (2012) Joshua J. Meeks et al. EUROPEAN UROLOGY
- Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987
- (2012) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequential Therapy with Gemcitabine and Carboplatin Followed by Paclitaxel as First Line Treatment for Advanced Urothelial Cancer
- (2012) Joseph G Kattan et al. Journal of Cancer
- Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial
- (2011) F. Cognetti et al. ANNALS OF ONCOLOGY
- Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)
- (2011) Ioannis Boukovinas et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Gemcitabine or Gemcitabine Plus Oxaliplatin in the First-Line Treatment of Patients With Advanced Transitional Cell Carcinoma of the Urothelium Unfit for Cisplatin-Based Chemotherapy: A Randomized Phase 2 Study of the French Genitourinary Tumor Group (GETUG V01)
- (2011) Stéphane Culine et al. EUROPEAN UROLOGY
- Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75
- (2011) Noah M. Hahn et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]
- (2010) P. Albers et al. ANNALS OF ONCOLOGY
- Final Results of Sequential Doxorubicin Plus Gemcitabine and Ifosfamide, Paclitaxel, and Cisplatin Chemotherapy in Patients With Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium
- (2009) Matthew I. Milowsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802)
- (2008) Robert Dreicer et al. CANCER
- Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Carcinoma of the Bladder
- (2008) David C. Smith et al. JOURNAL OF UROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now